Exploring Mechanistic Study: Potential of Luseogliflozin on Restoration of Cardiomyocyte Energy Metabolism in Diabetic Patients with Coronary Artery Disease

Exploring Mechanistic Study: Potential of Luseogliflozin on Restoration of Cardiomyocyte Energy Metabolism in Diabetic Patients with Coronary Artery Disease - EXPLORE-CAD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037291

Enrollment

Registered

2019-07-05

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Luseogliflozin Standard Therapy without Luseogliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients who are planed percutaneous coronary intervention for the treatment of angina pectoris.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Unstable angina 3. 3-vessel disease 4. insulin usage 5. eGFR < 45ml/min/1.73m2 6. Liver failure (Child-Pugh: Type C) 7. Severe Heart failure (NYHA Stage4) 8. BMI <18.5kg/m2 9. Allergic reaction to drugs 10. Pregnant, breastfeeding patients or suspected patients 11. Patients with malignant diseases

Design outcomes

Primary

Measure	Time frame
Changes of blood metabolic profiles	—

Secondary

Measure	Time frame
Change of diastolic dysfunction	—

Countries

Japan

Contacts

Public ContactYuichiro Arima

Kumamoto University Cardiovascular Medicine

arimay@kumamoto-u.ac.jp096-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026